CaptainObvious, I included the chart and link to show and prove that if DCVax-L is priced at $250,000 initially, it would still be 1 of the cheapest approved ATMPs in the world.
However, I do agree that once Flaskworks is approved to be included in the DCVax-L production process, the cost to make DCVax-L will go down, and the price to patients will also go down.
There are other approved cell therapy ATMPs that are price at multiple $millions. At $250,000, the annual cost (over 3 to 10 years) of DCVax would be a fraction of what these other approved cellular therapies cost.
When a regimen of DCVax-L vaccine is produced for a patient, all of the doses are produced at 1 time. Depending on how much of the tumor that is resected, enough DCVax-L vaccine can be produced for up to 3 to 10 years of doses.
Unfortunately, there is a concerted effort on this message board to make it appear that DCVax-L is over-priced or too expensive. But, the opposite is true. DCVax-L is safe, efficacious and very affordable, compared to all the other approved ATMPs.
Bullish
Market Data 
Markets 
AI
